Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Sep 2;2013(9):CD008415.
doi: 10.1002/14651858.CD008415.pub2.

Post-surgical chemotherapy versus surgery alone for resectable gastric cancer

Rafael Diaz-Nieto  1 , Rafael Orti-Rodríguez, Marc Winslet
Affiliations
Meta-Analysis

Post-surgical chemotherapy versus surgery alone for resectable gastric cancer

Rafael Diaz-Nieto et al. Cochrane Database Syst Rev. .

Abstract

Background: For gastric cancer surgery is the mainstay treatment. Chemotherapy seems to improve the survival results. But chemotherapy is not a complication-free therapy and its role has been questioned by some trials.

Objectives: To determine whether post-surgical chemotherapy should be used routinely in resectable gastric cancer.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded (July 2013).

Selection criteria: Randomised controlled trials (RCT) comparing post-surgical chemotherapy versus surgery alone for resectable gastric cancer.

Data collection and analysis: Two authors independently assessed trials for inclusion and independently extracted the data. We analysed the data with both the fixed-effect and the random-effects models using the RevMan analysis software. We calculated the hazard ratio (HR) with 95% confidence interval (CI) based on intention-to-treat or available case analysis.

Main results: The authors identified 34 studies (7824 patients) reporting overall survival (OS) and only 15 reporting disease free survival (DFS) as well. Post-surgical chemotherapy showed an improvement in OS (HR 0.85; 95% CI 0.80 to 0.90) and an improvement in DFS (HR 0.79; 95% CI 0.72 to 0.87), although all the trials had a high risk of bias.The planned analysis of quality of life, return to work, and number of hospital admissions was impossible to complete as the outcome data for the analysis were not available from any trials.

Authors' conclusions: Post-surgical chemotherapy should be used routinely for resectable gastric cancer where possible. Further RCTs are needed to determine the role at each stage of disease.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1
1
Study flow diagram.
2
2
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
3
3
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
4
4
Forest plot of comparison: 1 Post‐surgical chemotherapy versus surgery alone, outcome: 1.1 Overal survival.
5
5
Funnel plot of comparison: 1 Post‐surgical chemotherapy versus surgery alone, outcome: 1.1 Overal survival.
6
6
Forest plot of comparison: 1 Post‐surgical chemotherapy versus surgery alone, outcome: 1.2 Disesase free survival.
1.1
1.1. Analysis
Comparison 1 Post‐surgical chemotherapy versus surgery alone, Outcome 1 Overal Survival.
1.2
1.2. Analysis
Comparison 1 Post‐surgical chemotherapy versus surgery alone, Outcome 2 Disesase free survival.
2.1
2.1. Analysis
Comparison 2 Subgroup analysis, Outcome 1 Chemobased OS.
2.2
2.2. Analysis
Comparison 2 Subgroup analysis, Outcome 2 Stage OS analysis.
2.3
2.3. Analysis
Comparison 2 Subgroup analysis, Outcome 3 Lymph node mets analysis.
2.4
2.4. Analysis
Comparison 2 Subgroup analysis, Outcome 4 Chemobased DFS.
2.5
2.5. Analysis
Comparison 2 Subgroup analysis, Outcome 5 Low Risk of Bias.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Allum 1989 {published data only}
    1. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. 5 year follow‐up of first British Stomach Cancer Group trial. Lancet March, 1989;1(8638):571‐4. - PubMed
Bajetta 2002 {published data only}
    1. Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, et al. Adjuvant chemotherapy in gastric cancer: 5‐year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Annals of Oncology 2002;13:299–307. - PubMed
Bonfanti 1988 {published data only}
    1. Bonfanti G. Adjuvant treatments following curative resection for gastric cancer. The Italian Gastrointestinal Tumor Study Group. British Journal of Surgery 1988;75(11):1100‐4. - PubMed
Bouché 2005 {published data only}
    1. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, et al. Adjuvant chemotherapy with 5‐fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7‐year results of the FFCD randomized phase III trial (8801). Annals of Oncology 2005;16(9):1488–97. - PubMed
Chipponi 2004 {published data only}
    1. Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, et al. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. American Journal of Surgery 2004;187(3):440–5. - PubMed
Chou 1994 {published data only}
    1. Chou FF, Sheen‐Chen SM, Liu PP, Chen FC. Adjuvant chemotherapy for resectable gastric cancer: a preliminary report. Journal of Surgical Oncology 1994;57(4):239‐42. - PubMed
Cirera 1999 {published data only}
    1. Cirera L, Balil A, Batiste‐Alentorn E, Tusquets I, Cardona T, Arcusa A, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. Journal of Clinical Oncology 1999;17(12):3810‐5. - PubMed
Coombes 1990 {published data only}
    1. Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. Journal of Clinical Oncology 1990;8(8):1362‐9. - PubMed
De Vitta 2007 {published data only}
    1. Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Martino N, et al. Adjuvant chemotherapy with epirubicin, leucovorin,5‐fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase IIItrial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Annals of Oncology 2007;18(8):1354‐8. - PubMed
Di Costanzo 2008 {published data only}
    1. Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. Journal of National Cancer Institute 2008;100(6):388–98. - PubMed
Douglas 1982 {published data only}
    1. Douglas OH. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 1982;49(6):1116‐22. - PubMed
Engstrom 1985 {published data only}
    1. Engstrom PF, Lawn PT, Douglas HO, Brunner KW. Postoperative adjuvant 5‐fluorouracil plus methyl‐CCNU therapy for gastric cancer patients. Cancer 1985;55(9):1868‐73. - PubMed
Fielding 1983 {published data only}
    1. Fielding JW, Fagg SL, Jones BG, Ellis D, Hockey MS, Minawa A, et al. An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group. World Journal of Surgery 1983;7(3):390‐9. - PubMed
Fujimoto 1977 {published data only}
    1. Fujimoto S, Akao T, Itoh B, Koshizuka I, Koyano K. Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer. Annals of Surgery 1977;185(4):462‐6. - PMC - PubMed
Grau 1993 {published data only}
    1. Grau JJ, Estapé J, Alcobendas F, Pera C, Daniels M, Terés J. Positive results of adjuvant mitomycin‐C in resected gastric cancer: a randomised trial on 134 patients. European Journal of Cancer 1993;29(3):340‐2. - PubMed
Hallissey 1994 {published data only}
    1. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five‐year follow‐up. Lancet 1994;343(8909):1309‐12. - PubMed
Higgins 1983 {published data only}
    1. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5‐FU and methyl‐CCNU following resection for gastric carcinoma. Cancer 1983;52:1105‐12. - PubMed
Huguier 1980 {published data only}
    1. Huguier M, Destroyes JP, Baschet C, Henand F, Bernard PF. Gastric carcinoma treated by chemotherapy after resection: a controlled study. American Journal of Surgery 1980;139(2):197‐9. - PubMed
Kim 1992 {published data only}
    1. Kim JP, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Annals of Surgery 1992;216(3):269‐78. - PMC - PubMed
Krook 1991 {published data only}
    1. Krook JE, O'Connell MJ, Wieand HS, Beart RW Jr, Leigh JE, Kugler JW, et al. A prospective, randomized evaluation of intensive‐course 5‐fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991;67(10):2454‐8. - PubMed
Kulig 2010 {published data only}
    1. Kulig J, Kolodziejczyk P, Sierzega M, Bobrzynski L, Jedrys J, Popiela T, et al. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology 2010;78(1):54‐61. - PubMed
Lise 1995 {published data only}
    1. Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. Journal of Clinical Oncology 1995;13(11):2757‐63. - PubMed
Macdonald 1995 {published data only}
    1. Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, et al. Adjuvant chemotherapy with 5‐FU, adriamycin, and mitomycin‐C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Annals of Surgical Oncology 1995;2(6):488‐94. - PubMed
Nakajima 1999 {published data only}
    1. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plustegafur in serosa‐negative gastric cancer: a randomised trial. Lancet 1999;354(9175):273–7. - PubMed
Nakajima 2007 {published data only}
    1. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al. Randomized controlled trial of adjuvant uracil–tegafur versus surgery alone for serosa‐negative, locally advanced gastric cancer. British Journal of Surgery 2007;94(12):1468–76. - PubMed
Nashimoto 2003 {published data only}
    1. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa‐negative gastric cancer: Japan Clinical Oncology Group 9206‐1. Journal of Clinical Oncology 2003;21(12):2282‐7. - PubMed
Neri 2001 {published data only}
    1. Neri B, Cini G, Andreoli F, Boffi B, Francesconi D, Mazzanti R, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5‐year follow‐up. British Journal of Cancer 2001;84(7):878–80. - PMC - PubMed
Nitti 2006 EORTC {published data only}
    1. Nitti D, Wils J, Dos Santos JG, Fountzilas G, Conte PF, Sava C, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Annals of Oncology 2006;17(2):262–9. - PubMed
Nitti 2006 ICCG {published data only}
    1. Nitti J, Wils J, Dos Santos JG, Fountzilas G, Conte PF, Sava C, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCGD. Annals of Oncology 2006;17:262–9. - PubMed
Ochiai 1983 {published data only}
    1. Ochiai T, Sato H, Hayashi R, Asano T, Sato H, Yamamura Y. Postoperative adjuvant immunotherapy of gastric cancer with BCG‐cell wall skeleton. 3‐ to 6‐year follow up of a randomized clinical trial. Cancer Immunology, Immunotherapy 1983;14(3):167‐71. - PMC - PubMed
Popiela 1982 {published data only}
    1. Popiela T, Zembala M, Oszacki J, Jedrychowski W. A follow‐up study on chemoimmunotherapy (5‐fluorouracil and BCG) in advanced gastric cancer. Cancer Immunology, Immunotherapy 1982;13(3):182‐4. - PMC - PubMed
Popiela 2004 {published data only}
    1. Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer 2004;7:240–5. - PubMed
Sakuramoto 2007 {published data only}
    1. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S‐1, an oral fluoropyrimidine. New England Journal of Medicine 2007;357(18):1810‐20. - PubMed
Tentes 2006 {published data only}
    1. Tentes AA, Markakidis SK, Karanikiotis C, Fiska A, Tentes IK, Manolopoulos VG, et al. Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. Langenbeck's Archives of Surgery 2006;391(2):124–9. - PubMed

References to studies excluded from this review

Alcobendas 1983 {published data only}
    1. Alcobendas F, Milla A, Estape J. Mitomycin C as an adjuvant in resected gastric cancer. Annals of Surgery 1983;198(1):13‐7. - PMC - PubMed
Bresciani 2000 {published data only}
    1. Bresciani C, Gama‐Rodrigues J, Strassmann V, Waitzberg DL, Matsuda M, Pinotti HW. Long term (five‐year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study. "Revista do Hospital Das Clinicas; Faculdade de Medicina da Universidade de Sao Paulo" 2000;55(4):129‐36. - PubMed
Chen 2005 {published data only}
    1. Chen YP, Yang JS, Liu DT, Yang WP. Long‐term effects of proglumide on resection of cardiac adenocarcinoma. World Journal of Gastroenterology 2005;11(17):2549‐51. - PMC - PubMed
Chen 2011 {published data only}
    1. Chen S, Chen YB, Zhou ZW, Li W, Sun XW, Xu DZ, et al Li. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer. American Journal of Clinical Oncology 2011;34(3):309‐13. - PubMed
Cunninghan 2006 {published data only}
    1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 2006;355(1):11‐20. - PubMed
Estape 1991 {published data only}
    1. Estape J, Grau JJ, Lcobendas F, Curto J, Daniels M, Viñolas N, et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10‐year follow‐up. Annals of Surgery 1991;213(3):219‐21. - PMC - PubMed
Macdonald 2001 {published data only}
    1. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine 2001;345(10):725‐30. - PubMed
Moertel 1984 {published data only}
    1. Moertel CG, Childs DS, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5‐fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. Journal of Clinical Oncology 1984;2(11):1249‐54. - PubMed
Nio 1992 {published data only}
    1. Nio Y. A comprehensive multi institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK‐432 for patients after gastric‐cancer surgery. Annals of Surgery 1992;216(1):44‐54. - PMC - PubMed
Strong 2010 {published data only}
    1. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated normogram. Annals of Surgery 2010;251(4):640‐6. - PubMed
Yamamura 1986 {published data only}
    1. Yamamura Y, Yasue M, Kito T, Nakazato H, Yamada E. Adjuvant immunochemotherapy combined with OK‐432 following surgery of stomach cancer. Gan To Kagaku Ryoho [Cancer and Chemotherapy] 1986;10(7):1603‐9. - PubMed
Yu 1995 {published data only}
    1. Yu CC, Levison DA, Dunn JA, Ward LC, Demonakou M, Allum WH, et al. Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. British Journal of Cancer 1995;71(5):1106‐10. - PMC - PubMed

References to studies awaiting assessment

Bang 2012 {published data only}
    1. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open‐label, randomised controlled trial. Lancet 2012;379(9813):315‐21. - PubMed
Sasako 2011 {published data only}
    1. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five‐year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S‐1 versus surgery alone in stage II or III gastric cancer. Journal of Clinical Oncology 2011;29(33):4387‐93. - PubMed

Additional references

Al‐Batran 2010
    1. Al‐Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 2010;116(11):2511‐8. - PubMed
Alberts 2003
    1. Alberts SR, Cervantes A, Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Annals of Oncology 2003;14 Suppl 2:ii31‐6. [PUBMED: 12810455] - PubMed
Bozzetti 1999
    1. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal verus total gastrectomy for gastric cancer: five‐year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Annals of Surgery 1999;230(2):170‐8. - PMC - PubMed
Crew 2006
    1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World Journal of Gastroenterology 2006;12(3):354‐62. [PUBMED: 16489633] - PMC - PubMed
CRUK 2012
    1. Cancer Research UK. Stomach cancer. http://www.cancerresearchuk.org/cancer‐info/cancerstats/world/stomach‐ca... (accessed 03 December 2012).
Cuschieri 1999
    1. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long‐term results of the MRC randomized surgical trial. Surgical Co‐operative group. British Journal of Cancer 1999;79(9‐10):1522‐30. - PMC - PubMed
Davies 1998
    1. Davies J, Johnston D, Sue‐Ling H, Young S, May J, Griffith J, et al. Total or subtotal gastrectomy for gastric adenocarcinoma? A study of quality of life. World Journal of Surgery 1998;22(10):1048‐55. - PubMed
Degiuli 2004
    1. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. European Journal of Surgical Oncology 2004;30(3):303‐8. - PubMed
DeMets 1987
    1. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. - PubMed
Di Costanzo 2008b
    1. Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. Journal of the National Cancer Institute 2008;100(6):388‐98. - PubMed
Earle 1999
    1. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non‐Asian patients: revisiting a meta‐analysis of randomised trials. European Journal of Cancer 1999;35(7):1059‐64. [PUBMED: 10533448] - PubMed
EBCTCG 2008
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, et al. Adjuvant chemotherapy in oestrogen‐receptor‐poor breast cancer: patient‐level meta‐analysis of randomised trials. Lancet 2008;371(9606):29‐40. [PUBMED: 18177773] - PubMed
Egger 1997
    1. Egger M, Davey SG, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629‐34. - PMC - PubMed
Eguchi 2008
    1. Eguchi T, Kodera Y, Nakanishi H, Yokoyama H, Ohashi N, Ito Y, et al. The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: an in vivo study. In Vivo 2008;22(6):707‐12. [PUBMED: 19180995] - PubMed
FDA
    1. Food, Drugs Administration. US Food and Drug Administration home page. www.fda.gov (accessed 17 January 2012).
Ferguson 2007
    1. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. [CENTRAL: CD004421; DOI: 10.1002/14651858.CD004421.pub2] - DOI - PubMed
Forman 2009
    1. Forman D, Delaney B, Kuipers E, Malthaner R, Moayyedi P, Gardener E, et al. Cochrane Upper Gastrointestinal and Pancreatic Diseases Group. In: The Cochrane Library, Issue 2, 2010. Chichester: Wiley‐Blackwell. Updated quarterly.
GLOBOCAN 2008
    1. International Agency for Research on Cancer (WHO). Estimated cancer incidence, mortality, prevalence and disability‐adjusted life years (DALYs) worldwide in 2008. http://globocan.iarc.fr/ (accessed 03 December 2012).
Gouzi 1989
    1. Gouzi JL, Huguier M, Faqniez PL, Launois B, Flamant Y, Lacaine F, et al. Total gastrectomy versus partial gastrectomy of adenocarcinoma of the antrum. A French prospective controlled study. Annales de Chirugie 1989;43(5):356‐60. - PubMed
Gurusamy 2009
    1. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. British Journal of Surgery 2009;96(4):342‐9. - PubMed
Hartgrink 2004
    1. Hartgrink HH, Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. Journal of Clinical Oncology 2004;22(11):2069‐77. - PubMed
Hermans 1993
    1. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Velde CJ. Adjuvant therapy after curative resection for gastric cancer: meta‐analysis of randomized trials. Journal of Clinical Oncology 1993;11(8):1441‐7. - PubMed
Higgins 2002
    1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Hu 2002
    1. Hu JK, Chen ZX, Zhou ZG, Zhang B, Tian J, Chen JP, et al. Intravenous chemotherapy for resected gastric cancer: meta‐analysis of randomized controlled trials. World Journal of Gastroenterology 2002;8(6):1023‐8. [PUBMED: 12439918] - PMC - PubMed
Jemal 2010
    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA: A Cancer Journal for Clinicians 2010;60(5):277‐300. - PubMed
Jeung 2009
    1. Jeung HC, Rha SY, Shin SJ, Ahn JB, Roh JK, Park CH, et al. Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Cancer Chemotherapy and Pharmacology 2009;63(5):919‐27. [PUBMED: 18712389] - PubMed
Kim 1992b
    1. Kim JP, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Annals of Surgery 1992;216(3):269‐78; discussion 278‐9. [PUBMED: 1417176] - PMC - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed
Macaskill 2001
    1. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine 2001;20(4):641‐54. - PubMed
Mari 2000
    1. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta‐analysis of published randomised trials. Annals of Oncology 2000;11(7):837‐43. [PUBMED: 10997811] - PubMed
Mauri 2008
    1. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple‐treatments meta‐analysis of chemotherapy and targeted therapies in advanced breast cancer. Journal of the National Cancer Institute 2008;100(24):1780‐91. [PUBMED: 19066278] - PubMed
McCulloch 2003
    1. McCulloch P, Nita ME, Kazi H, Gama‐Rodriques J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD001964.pub2] - DOI - PubMed
Memon 2011
    1. Memon MA, Subramanya MS, Khan S, Hossain MB, Osland E, Memon B. Meta‐Analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Annals of Surgery 2011;253(5):900‐11. - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13. - PubMed
Nakajima 2002
    1. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002;5(1):1‐5. - PubMed
Newell 1992
    1. Newell DJ. Intention‐to‐treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837‐41. - PubMed
Oba 2006
    1. Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta‐analysis of centrally randomized controlled clinical trials in Japan. Journal of Chemotherapy 2006;18(3):311‐7. [PUBMED: 17129844] - PubMed
Okines 2010
    1. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A, ESMO Guidelines Working Group. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Annals of Oncology 2010;21(5):50‐4. - PubMed
Paoletti 2010
    1. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta‐analysis. JAMA 2010;303(17):1729‐37. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. [PUBMED: 9921604] - PubMed
RevMan 2008 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Shi 2010
    1. Shi Y, Zhou Y. The role of surgery in the treatment of gastric cancer. Journal of Surgical Oncology 2010;101:687‐92. - PubMed
Slanger 2009
    1. Slanger TE, Schwarzbach M, Hofheinz R, Kienle P, Jensen K, Kieser M, et al. Perioperative chemotherapy versus primary surgery for locoregionally advanced resectable adenocarcinoma of the stomach, gastroesophageal junction and lower esophagus. Cochrane Database of Systematic Reviews 2009, Issue 4. [CENTRAL: CD008107; DOI: 10.1002/14651858.CD008107.pub2] - DOI - PMC - PubMed
Songun 2010
    1. Songun I, Putter H, Kranenbarg EM, Sasako M, Velde CJ. Surgical treatment of gastric cancer: 15‐year follow‐up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncology 2010;11(5):439‐49. - PubMed
StatsDirect 2008 [Computer program]
    1. Stats Direct Ltd. StatsDirect statistical software. Version 2.7. England: StatsDirect Ltd, 2008.
Sun 2009
    1. Sun P, Xiang JB, Chen ZY. Meta‐analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. British Journal of Surgery 2009;96(1):26‐33. - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. [PUBMED: 17555582] - PMC - PubMed
Wagner 2005
    1. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD004064.pub2] - DOI - PubMed
WHO 1979
    1. World Health Organization. Handbook for reporting results of cancer treatment. Vol. WHO Offset Publication No. 48, Geneva: World Health Organization, 1979. [http://whqlibdoc.who.int/publications/9241700483.pdf]
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ 2008;336:601‐5. - PMC - PubMed
Wu 2006
    1. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncology 2006;7(4):309‐15. - PubMed
Wu 2012
    1. Wu B, Ye M, Chen H, Shen JF. Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics 2012;34(2):468‐79. - PubMed

Publication types

MeSH terms

LinkOut - more resources